Mayo Clinic Platform_Accelerate announces second cohort of AI startups

​Susan Barber Lindquis

ROCHESTER, Minn. — Mayo Clinic Platform_Accelerate has announced its second cohort of health tech startups, including national and international businesses. The program will help seven companies develop and validate their artificial intelligence-driven health care products or solutions and advance their business plans.

The immersive, 20-week program offers participants access to Mayo Clinic experts in regulatory, clinical, technology and business domains with a focus on AI model validation and clinical readiness. Technology experts from Google and Epic also will provide workshops for the participants.

"The only way we can transform health care is by bringing together clinical experts with technology innovators," says John Halamka, M.D., president of Mayo Clinic Platform, a strategic initiative to improve health care through insights and knowledge derived from data.

"Our Accelerate program combines emerging companies with breakthrough ideas, leaders from Mayo's clinical practice and our unique 'data behind glass' approach to algorithm development," Dr. Halamka says, describing the secure environment that allows companies to build algorithm models they can use for innovation, but the data never leave the Mayo Clinic Platform.
​
The program will help participants explore ways to improve health care in a variety of areas:

• AESOP Technology: Using machine learning on 3.2 billion patient visits, AESOP aims to make physician data entry easier, faster and less error-prone by automating diagnosis input and improving medication-related workflows. AESOP has offices in California, Colorado and Taiwan.
• Biotia: By fighting infectious diseases with AI and genomics, Biota is leveraging new DNA sequencing technology to enable personalized, data-driven discovery of microorganisms that cause illness. The company is based in New York City.
• Delfina: Tackling the maternal health crisis, Delfina’s software is monitoring health data to assess pregnancy risks, coordinate with providers and deliver a personalized care plan to improve pregnancy outcomes. Delfina has offices in San Francisco, New York City and Rochester, Minnesota.
• Dynocardia: Using wearable technology for accurate real-world continuous blood pressure and other advanced heart function measures, Dynocardia is leveraging AI to enable early detection before serious health events. The company is based in Cambridge, Massachusetts.
• ImpriMed: To personalize human and animal cancer treatment, ImpriMed aims to validate an oncology platform to provide patients and clinicians with the best predictive information for individual cancer patients. The company has offices in Palo Alto, California, and Seoul, South Korea.
• Predicta Med: To shorten the diagnostic journey and enable early and effective treatment, Predicta Med is creating an AI-based decision support platform for early detection of autoimmune diseases. The company is based in Tel Aviv, Israel.
• SOAP Health: SOAP (Subjective, Objective, Assessment, Plan) Health seeks to enhance physician productivity and insight to ensure accurate and timely prediagnosis — made before occurrence of symptoms — and diagnosis. The company is based in Boca Raton, Florida.

深入瞭解